Drug Profile

Imatinib dry powder inhalation - Jade Biosciences

Alternative Names: AV-101 - Jade Biosciences

Latest Information Update: 07 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aerovate Therapeutics
Developer Jade Biosciences
Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
Mechanism of Action Angiogenesis inhibitors; Bcr-Abl tyrosine kinase inhibitors; Discoidin domain receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pulmonary arterial hypertension
New Molecular Entity No

28 Apr 2025 Aerovate Therapeutics has merged with Jade Biosciences to form Jade Biosciences
17 Jun 2024 Aerovate Therapeutics terminates phase II/III trial IMPAHCT-FUL for Pulmonary arterial hypertension (In adult, In the elderly) in the Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Israel, Italy, Latvia, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United Kingdom, USA (Inhalation, Powder) based upon unmet endpoints (NCT05557942)
17 Jun 2024 Aerovate Therapeutics terminates phase-II/III IMPAHCT clinical trials in Pulmonary arterial hypertension in Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Israel, Italy, Latvia, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United Kingdom, USA (Inhalation) based upon unmet endpoints (NCT05036135) (EudraCT2021-001910-13)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com